TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03580018
Drug: Tranexamic Acid Powder
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ten mL of Tranexamic Acid(100 mg/mL) was injected into the joint at the end of the operation.
Study: NCT04521205
Drug: fecal microbiota capsule
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a capsule full of fecal microbiota extracting from the health
Study: NCT00110201
Drug: Nesiritide
Normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03667326
Drug: Aspirin tablet
Normalized name: Aspirin Tablets
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low dose aspirin, 81mg tablets, PO
Study: NCT03835520
Drug: Molecular Target
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Targeted agents will be administered according to standard of care and reimbursement modalities in Belgium. Targeted agents will be administered according to manufacturer's instructions.
Study: NCT01011426
Drug: Bisacodyl
Normalized name: Bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg po 6 hours postoperatively, repeat in 12 hours if no flatus
Study: NCT02539537
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02539537
Drug: Folinic Acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02539537
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02539537
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02539537
Drug: L-folinic
Normalized name: L-Folinic acid
DrugBank: Levoleucovorin (DB11596)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02274246
Drug: gadobutrol
Normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadobutrol administration in healthy volunteers
Study: NCT00567710
Drug: BL - 1020
Normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day
Study: NCT00567710
Drug: BL - 1020
Normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BL 1020 20-30 mg/day
Study: NCT02080416
Drug: Nelfinavir
Normalized name: Nelfinavir
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nelfinavir will be given 3000 mg orally twice daily on days 1-14 of a 14-day cycle. NFV will be continued in patients tolerating therapy for 4 cycles (8 weeks).
Study: NCT02123381
Drug: cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400mg/m2/week, 2 hours,iv,at week 1;250mg/m2/week,1hour,iv,at week 2-4
Study: NCT01719653
Drug: MiraLAX
Normalized name: Miralax
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MiraLAX consumed as described in each arm.
Study: NCT01719653
Drug: MoviPrep
Normalized name: MoviPrep
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MoviPrep consumed as described in each arm.
Study: NCT00976339
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol is a vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Cholecalciferol is used to treat or prevent many conditions caused by a lack of vitamin D.~Cholecalciferol will be available in gel capsule form at 10,000 IU (0.25 mg cholecalciferol) each.
Study: NCT00567710
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsules
Study: NCT03609047
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: CDK4/6 inhibitor
Study: NCT03609047
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjuvant Chemotherapy
Study: NCT03239210
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-HT3 (serotonin receptor type 3) antagonist commonly used to treat nausea and vomiting
Study: NCT00733993
Drug: Amphetamine
Normalized name: Amphetamine
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Across five separate testing days, subjects were administered two placebo doses, 20 mg damphetamine,150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
Study: NCT00107120
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram 10mg per day for three weeks, 10-20mg per day for up to the remaining 5 weeks
Study: NCT01281150
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01281150
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT01281150
Drug: Veliparib
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02782403
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02782403
Drug: Bosutinib
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01954043
Drug: Dabrafenib 150 mg twice a day (BID)
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib dosed at 150mg twice a day from Day 1 to the morning of Day 29
Study: NCT01954043
Drug: Rabeprazole 40 mg once daily (OD)
Normalized name: lisinopril
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole dosed at 40mg each morning on Days 16 to 19
Study: NCT01954043
Drug: Rifampin 600 mg OD
Normalized name: rifampin 600 MG
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin dosed at 600mg each morning on Days 20 to 29
Study: NCT00718354
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily dose of 1mg/Kg of body weight for 6 months
Study: NCT00892021
Drug: NSA-789
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02835716
Drug: roflumilast
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: DALIRESP is used in adults with severe chronic obstructive pulmonary disease (COPD) to decrease the number of flare-ups or the worsening of COPD symptoms (exacerbations
Study: NCT03010072
Drug: low-dose sucroferric oxyhydroxide
Normalized name: Sucroferric Oxyhydroxide
DrugBank: Ferric sulfate (DB11171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250 mg suroferric oxyhydroxide
Study: NCT03010072
Drug: high-dose sucroferric oxyhydroxide
Normalized name: Sucroferric Oxyhydroxide
DrugBank: Ferric sulfate (DB11171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2000 mg suroferric oxyhydroxide
Study: NCT04847024
Drug: Parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 40 mg IV
Study: NCT04847024
Drug: Dexketoprofen
Normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg IV
Study: NCT03506477
Drug: Vehicle foam
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: for 4 weeks
Study: NCT02075125
Drug: Prasugrel 60 mg
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose.
Study: NCT02075125
Drug: Ticagrelor 180 mg
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose.
Study: NCT00167310
Drug: Eicosapentaenoic acid (omega-3 fatty acid)
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 g of Eicosapentaenoic acid in 4 x 500 mg capsules daily for baseline, 1 month, 2 months and 4 months
Study: NCT03818308
Drug: Sofosbuvir and Velpatasvir
Normalized name: sofosbuvir and velpatasvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All subjects will receive one film-coated tablet of sofosbuvir/velpatasvir (400/100 mg) orally once daily for 8 weeks.
Study: NCT00816335
Drug: 18F-FDG Injection
Normalized name: (18F)-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients undergoing a preoperative PET/CT scan the day of surgery, are required to have fasted for at least 4 hours prior to the anticipated preoperative PET/CT scan. Patients participating in this pilot study (whether they have had their preoperative PET/CT scan prior to the day of surgery or whether they are having their preoperative PET/CT scan on the day of surgery) will receive a preoperative IV injection into a peripheral vein of 15 mCi of 18FFDG at time interval of approximately 60 to 180 minutes prior to anticipated time of surgery.
Study: NCT00816335
Drug: 18F-FDG for patients with Bladder Cancer
Normalized name: (18F)-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elimination of 18F-FDG by the urinary system and accumulation in the bladder impacts the differentiation between residual 18F-FDG in the bladder and activity in tumor and adjacent lymph nodes. For patients with bladder cancer, the urinary catheter routinely placed in the operating room will be inserted in the Ambulatory Surgery Unit (ASU) by the urologist on-service or the urology research nurse. A 3-way Foley catheter will be placed for continuous bladder irrigation with Normal Saline (0.9%) initiated in ASU and will continue for the duration of the imaging procedure at a standard rate of 10cc/minute. The urology research nurse will transport the patient to and from the PET/CT area and monitor the continuous bladder irrigation during the imaging session.
Study: NCT00876928
Drug: vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: liquid vitamin D3 dissolved in medium chain triglyceride once a week
Study: NCT03339128
Drug: Eluxadoline
Normalized name: ELUXADOLINE
DrugBank: Eluxadoline (DB09272)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral tablets
Study: NCT00521183
Drug: Cytochlor
Normalized name: Cytochlor
DrugBank: Cytochlor (DB12383)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study's starting dose of CldC is 50 mg/m2/day. The dose of CldC will be escalated / de-escalated for patients. Patients will receive CldC+H4U on 3 days (Wed, Thr, Fri) in week 1, which precedes the initiation of radiation therapy. Patients will receive H4U and CldC IV by bolus infusion. Treatment with CldC+H4U will then continue for 5 days (Mon-Fri) during each of weeks 2 and 3, and will be accompanied by radiation therapy at 3 Gy/fraction initiated 3-4 h after bolus infusion of CldC+H4U. Treatment with CldC+H4U and radiation will then stop at the end of week 3.
Study: NCT00521183
Drug: Tetrahydrouridine
Normalized name: Tetrahydrouridine
DrugBank: Tetrahydrouridine (DB12484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A fixed dose of H4U at 720 mg/m2/day will be used, regardless of the dose of CldC administered. H4U will be delivered by an IV bolus infusion over a period of 5 minutes, followed 5 minutes later by an IV bolus infusion of CldC. Patients will receive CldC+H4U on 3 days (Wed, Thr, Fri) in week 1, which precedes the initiation of radiation therapy. Patients will receive H4U and CldC IV by bolus infusion. Treatment with CldC+H4U will then continue for 5 days (Mon-Fri) during each of weeks 2 and 3, and will be accompanied by radiation therapy at 3 Gy/fraction initiated 3-4 h after bolus infusion of CldC+H4U. Treatment with CldC+H4U and radiation will then stop at the end of week 3.
Study: NCT02795429
Drug: Spartalizumab
Normalized name: Spartalizumab
DrugBank: Spartalizumab (DB14892)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spartalizumab administered via intravenous (i.v.) infusion once every 3 weeks (Q3W)
Study: NCT02795429
Drug: Capmatinib
Normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capmatinib administered orally as a tablet on a continuous twice daily (BID) dosing schedule
Study: NCT04317703
Drug: Gemigliptin tartrate sesquihydrate and metformin
Normalized name: metformin and ertugliflozin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Each tablet contains gemigliptin tartrate sesquihydrate 68.9 mg (equivalent to gemigliptin pure free base 50 mg) and metformin hydrochloride 1000.0 mg.
Study: NCT04317703
Drug: gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release
Normalized name: metformin and gemigliptin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zemiglo Tablet 50 mg: Each tablet contains gemigliptin tartrate sesquihydrate, equivalent to 50 mg gemigliptin.~Glucophage XR 1000 mg: Each tablet contains metformin hydrochloride 1000 mg (equivalent to 780 mg of metformin base).
Study: NCT00276029
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00000301
Drug: Amantadine
Normalized name: Amantadine
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03802591
Drug: CS1001 monoclonal antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participant will receive CS1001 monoclonal antibody by intravenous infusion every 3 weeks(Q3W), for up to 24 months
Study: NCT03363763
Drug: Sirolimus 0.2%
Normalized name: SIROLIMUS 0.2% GEL,TOP
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ointment for topical administration hs x 12 weeks
Study: NCT03363763
Drug: Sirolimus 0.4%
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ointment for topical administration hs x 12 weeks
Study: NCT01990209
Drug: Orteronel
Normalized name: Orteronel
DrugBank: Orteronel (DB12066)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00350181
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Immunosuppressant beginning day -3 with 12 mg oral loading dose, 4 mg/day orally for adults
Study: NCT00350181
Drug: MMF
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressant given through IV on day 0 at 15 mg/kg twice daily ≥ 2hr after the completion for the donor cell infusion
Study: NCT00350181
Drug: BCNU
Normalized name: BCNU
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 mg/kg, IV
Study: NCT00350181
Drug: VP-16
Normalized name: Provp-16i
DrugBank: Etoposide toniribate (DB17255)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/kg, IV
Study: NCT00350181
Drug: FTBI
Normalized name: Fluticasone Terephthalate Budesonide Inhalation
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1320 cGy delivered in 11 120 cGy fractions over 4 day
Study: NCT00350181
Drug: BU
Normalized name: Ibu
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: BU 1 mg/kg every 6hr x 4 doses, IV
Study: NCT03089619
Drug: Human-Spongiosa
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: after tooth extraction, the dental alveolus is filled with the bone substitute material (Human-Spongiosa) and covered with a membrane (mucoderm®)
Study: NCT00427973
Drug: cediranib maleate
Normalized name: maleate
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT06004947
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally.
Study: NCT06004947
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT06004947
Drug: Rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT00295594
Drug: tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immunosuppression
Study: NCT01506141
Drug: Idursulfase-IT
Normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive Idursulfase-IT once monthly at the dose used in study HGT-HIT-045 via intrathecal drug delivery device (IDDD).
Study: NCT02708459
Drug: Intravenous morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Boluses of intravenous morphine (2 mg) will be given to patients if Visual analogue scale (VAS) more than 3
Study: NCT03802591
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered as an IV infusion on Day 1 Q3W
Study: NCT01506141
Drug: Elaprase
Normalized name: Elaprase
DrugBank: Idursulfase (DB01271)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive weekly IV infusions of commercially available Elaprase.
Study: NCT01037244
Drug: Udenafil
Normalized name: udenafil
DrugBank: Udenafil (DB06267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets via oral administration before an attempt at sexual intercourse.
Study: NCT00063154
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab was supplied as a single-use liquid formulation.
Study: NCT04541186
Drug: Pegozafermin
Normalized name: Pegozafermin
DrugBank: Pegozafermin (DB19062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT01245777
Drug: ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 women with Restless Legs Syndrome (RLS) and iron deficiency and/ or anaemia in the third trimester of pregnancy will receive intravenous Ferric carboxymaltose in one or two single doses.
Study: NCT04426487
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramusculer progesterone
Study: NCT02256969
Drug: Blephamide
Normalized name: Blephamide
DrugBank: Sulfacetamide (DB00634)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01224795
Drug: Peramivir
Normalized name: Peramivir
DrugBank: Peramivir (DB06614)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adults (≥ 18 years): Peramivir 600 mg, administered intravenously. Adolescents (12 to \< 18 years): Peramivir 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously.
Study: NCT03355170
Drug: Lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active comparator
Study: NCT01036802
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients on the active treatment arm will receive warfarin to achieve a target international normalized ratio of between 2 and 3
Study: NCT04585997
Drug: Mepolizumab
Normalized name: Mepolizumab
DrugBank: Mepolizumab (DB06612)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Mepolizumab 100mg subcutaneous injection monthly for 6 months
Study: NCT04585997
Drug: Omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab subcutaneous injection every 2-4 weeks (dosage determined by the Omalizumab nomogram).
Study: NCT02025608
Drug: Pramipexole
Normalized name: Pramipexole
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00313001
Drug: biphasic insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00313001
Drug: exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01341080
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Varenicline 1mg twice daily for eight weeks after a one week dose escalation period.
Study: NCT01341080
Drug: Sugar pill
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg twice daily for eight weeks after a one week dose escalation phase.
Study: NCT02724020
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus capsules.
Study: NCT01995370
Drug: aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (81mg or 100mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
Study: NCT01995370
Drug: clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel (50mg or 75mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
Study: NCT01995370
Drug: cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol (100mg twice daily) will be orally administered. The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
Study: NCT00582790
Drug: IL2
Normalized name: Ad-IL2
DrugBank: TG1024 (DB06180)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-2 will be given at a starting dose of 7 MU/m2/day by subcutaneous injection days 1-5, on weeks 1 through 3, in four week (28 days) cycles.
Study: NCT04140409
Drug: Sandostatin
Normalized name: Sandostatin
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will be treated with octreotide LAR intramuscular injections at maximum doses of 60 mg every 4 weeks or a frequency up to 30 mg octreotide LAR each 2 weeks. Change of dose or frequency is left at the discretion of the investigator until symptom control is obtained.